Anzeige
Mehr »
Login
Dienstag, 25.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Jackpot-News: Diese Aktie rockt mit bahnbrechender Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
552 Leser
Artikel bewerten:
(2)

Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®

Finanznachrichten News

ORLANDO, FL / ACCESSWIRE / June 9, 2023 / RedChip Companies will air new interviews with Unicycive Therapeutics, Inc. (Nasdaq:UNCY) and Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

  • Unicycive Therapeutics, Inc. (Nasdaq: UNCY): https://uncyinfo.com/interview_access
  • Alarum Technologies Ltd.: https://alarinfo.com/interview_access

About The RedChip Money Report®

The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Unicycive Therapeutics, Inc.

Unicycive is focused on two kidney diseases with large unmet medical needs. We are developing Renazorb, an investigational phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. We plan to file a New Drug Application (NDA) for Renazorb with the U.S. Food and Drug Administration (FDA) mid-year. We are also developing UNI-494, a new chemical entity with a novel mechanism of action that restores mitochondrial function in acute and chronic diseases. Our initial target for UNI-494 is acute kidney injury (AKI), for which there are currently no FDA-approved medicines. For more information, please visit www.unicycive.com.

About Alarum Technologies Ltd.

Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) is a global provider of internet access solutions. The Company operates primarily in two distinct segments: solutions for enterprises and solutions for consumers.

The solutions by NetNut, our Enterprise Internet Access arm, are based on our world's fastest and most advanced and secured hybrid proxy network, enabling our customers to collect data anonymously at any scale from any public sources over the web. Our network comprises both exit points based on our proprietary reflection technology and hundreds of servers located at our Internet Service Providers partners around the world. The infrastructure is optimally designed to guarantee privacy, quality, stability, and the speed of the service.

Our Consumer Internet Access arm offers privacy and cybersecurity solutions to end users. These solutions are designed to allow users to take charge of their online privacy with a powerful, secured and encrypted connection. The solutions are designed for basic and advanced use cases, ensuring complete protection of personal and digital information.

For more information about Alarum and its internet access solutions for enterprises and consumers, please visit www.alarum.io.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com

--END--

SOURCE: RedChip

View source version on accesswire.com:
https://www.accesswire.com/760280/Unicycive-Therapeutics-Inc-and-Alarum-Technologies-Ltd-Interviews-to-Air-on-Bloomberg-TV-on-the-RedChip-Money-Report

© 2023 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.